Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia. Effects of LDL-apheresis.

Cytokine

Volumn 61, Issue 1, 2013, Pages 194-198

  Nenseter, Marit S ^a,b   Narverud, Ingunn ^a,c,d   Græsdal, Asgeir ^e   Bogsrud, Martin P ^a,f   Halvorsen, Bente ^a,b   Ose, Leiv ^a,c   Aukrust, Pål ^a,b,g   Holven, Kirsten B ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO METROPOLITAN UNIVERSITY   (Norway)

^e Vestfold Center of Internal Medicine   (Norway)

^f Møre and Romsdal Health Trust   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiovascular disease; Inflammation; LDL cholesterol; LDL apheresis; Plaque instability

Indexed keywords

ATORVASTATIN; EZETIMIBE; GELATINASE B; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; ROSUVASTATIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CELL NUCLEUS MATRIX; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME RELEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MALE; METABOLIC PARAMETERS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCHOOL CHILD; SERUM MATRIX METALLOPROTEINASE 9 TISSUE INHIBITOR OF METALLOPROTEINASE 1 RATIO;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHILD; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84869869874     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.09.016     Document Type: Article

References (26)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
4. Newby A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007, 17:253-258.
5. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
6. Halvorsen B., Otterdal K., Dahl T.B., Skjelland M., Gullestad L., Øie E., et al. Atherosclerotic plaque stability-what determines the fate of a plaque?. Prog Cardiovasc Dis 2008, 51:183-194.
7. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
8. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004, 160:407-420.
9. Weisgraber K.H., Innerarity T.L., Newhouse Y.M., Young S.G., Arnold K.S., Krauss R.M., et al. Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. Proc Natl Acad Sci USA 1988, 85:9758-9762.
10. Moriarty P.M. LDL-apheresis therapy. Curr Treat Options Cardiovasc Med 2006, 8:282-288.
11. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M., et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010, 21:492-498.
12. Moriarty P.M., Gibson C.A., Shih J., Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 2001, 158:495-498.
13. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apheresis Dial 2003, 7:431-434.
14. Empen K., Otto C., Brödl U.C., Parhofer K.G. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apheresis 2002, 17:38-43.
15. Rovers C., Netea M.G., de Bont N., Demacker P.N., Jacobs C., Kullberg B.J., et al. LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998, 141:99-105.
16. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
17. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apheresis 2009, 24:247-253.
18. Stefanutti C., Vivenzio A., Di Giacomo S., Ferraro P.M. Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis. Cytokine 2011, 55:245-250.
19. Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: results of 35 years of follow up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol, in press. doi:10.1016/j.jacl.2012.03.004.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
21. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
22. Holven K.B., Halvorsen B., Schulz H., Aukrust P., Ose L., Nenseter M.S. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest 2003, 33:555-560.
23. Holven K.B., Halvorsen B., Bjerkeli V., Damås J.K., Retterstøl K., Mørkrid L., et al. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke 2006, 37:1731-1736.
24. Dihazi H., Koziolek M.J., Söllner T., Kahler E., Klingel R., Neuhoff R., et al. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transpl 2008, 23:2925-2935.
25. Stefanutti C., Morozzi C., Petta A. Lipid and low-density-lipoprotein apheresis. effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine 2011, 56:842-849.
26. Nakamura T., Matsuda T., Suzuki Y., Ueda Y., Koide H. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J 2003, 49:430-434.